NCT00604682已完成2 期
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 19
- 试验地点
- 3
- 主要终点
- To evaluate the pharmacodynamic effect of orally administered CC10004 when taken for 29 days in reducing epidermal thickness in subjects with severe plaque-type psoriasis.
研究概览
简要总结
Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Any serious medical condition, laboratory abnormality , or psychiatric illness that would prevent the subject from signing the informed consent form
- •Pregnant or lactating females
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- •Current erythrodermic, guttate, or pustular psoriasis
- •Use of medication that is metabolized by the CYP3A4 or CYP2A6 pathways within the 14 days of study medication initiation and/or required use of such medication during study treatment.
- •Drinking or ingesting grapefruits, grapefruit juice or grapefruit containing products within 14 days of study medication initiation
- •Use of topical therapy ( topical steroids, topical vitamin A or D analog preparations, tacrolimus, pimecrolimus, or anthralin) within 14 days of study medications initiation (Exception: Non-medicated emollients and tar shampoo will be allowed)
- •Use of systemic therapy for psoriasis
- •Use or phototherapy within 28 days of study medication initiation
- •Use Humira or Remicade within 3 months of study medication initiation
- •Use of Enbrel within 56 days of study medication initiation
- •Use of Raptiva within 56 days of study medication initiation
- •Use of Amevive within 6 months of study medication initiation
- •Use of any investigational drug within 30 days of study medication initiation or 5 half lives if known
- •History of clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease or other major diseases
- •Clinically significant abnormality on 12-lead ECG at screening
- •Positive HIV, Hepatitis B or Hepatitis C laboratory result at screening
- •History of active tuberculosis within previous 3 years
- •Clinically significant abnormality on the chest x-ray at screening or on CXR taken within 6 months of screening
- •History of positive purified protein derivative (PPD) test at screening
- •History of malignancy within previous five years
- •Evidence of skin conditions at the time of screening visit other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis
研究组 & 干预措施
Administration of CC10004
Experimental
干预措施: CC10004 (Drug)
结局指标
主要结局
To evaluate the pharmacodynamic effect of orally administered CC10004 when taken for 29 days in reducing epidermal thickness in subjects with severe plaque-type psoriasis.
时间窗: 29 days
次要结局
- To evaluate the safety of orally administered CC10004 in subjects with severe plaque-type psoriasis during the treatment and follow up phases.(58 days)
- To explore the clinical efficacy of orally administered CC10004 when taken for 29 days in subjects with severe plaque-type psoriasis.(29 days)
- To explore the clinical efficacy of CC10004 when taken for 29 days in subjects with psoriatic arthritis.(29 days)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisPsoriasisNCT02576678Amgen42
Unknown
1 期
RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05122572Wuxi People's Hospital36
已完成
早期 1 期
TPO-Mimetic Use in Children for Hematopoietic FailureBone Marrow Failure DisordersRefractory Cytopenia of ChildhoodThrombocytopeniaMyelodysplastic Syndrome(MDS)Aplastic AnemiaNCT04478227Anjali Sharathkumar15
已完成
不适用
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened InhibitorsBasal Cell CarcinomaNCT01529450Anne Chang11
招募中
1 期
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentGliomaNCT05460507Plus Therapeutics40